Lynch Syndrome Clinical Trial
Official title:
Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study
The investigators will evaluate the feasibility of an intervention to improve Lynch syndrome cascade screening uptake. The investigators will conduct a pilot study among 15 patients diagnosed with Lynch Syndrome and 5 genetic counselors to assess the feasibility and intermediate outcomes of an educational workbook containing exercises and resources to improve family communication among individuals with Lynch Syndrome and first-degree relatives of individuals with Lynch Syndrome.
Status | Recruiting |
Enrollment | 19 |
Est. completion date | August 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients must have been diagnosed with Lynch Syndrome within the last 365 days. - Patients and genetic counselors must be age 18 or older. - Patients must be receiving care from genetic counselors at Ohio State University Comprehensive Cancer Center or at UNC Health System. - Genetic counselors must provide Lynch Syndrome counseling for patient participants at Ohio State University Comprehensive Cancer Center or at UNC Health System. - Patients and genetic counselors must be able to speak and read in English. - Patients and genetic counselors must review informed consent documents and provide verbal consent to participate in the study. Exclusion Criteria: There are no exclusion criteria for study participants. |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
United States | The Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
UNC Lineberger Comprehensive Cancer Center | National Center for Advancing Translational Sciences (NCATS), North Carolina Translational and Clinical Sciences Institute, University of North Carolina, Chapel Hill |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient Acceptability of Workbook Assessed through Likert Score Scale | Patients will score the workbook on 7 acceptability criteria on a scale of 1 (very unacceptable) to 5 (very acceptable). The sum of the 7 criteria scores is the total acceptability score. A score of 80% or higher of the maximum score indicates an acceptable intervention. Acceptability scores will be collected through an electronic survey questionnaire. | Post 4 Weeks of Workbook Use | |
Primary | Genetic Counselor Acceptability of Workbook Assessed through Likert Score Scale | Genetic counselors will score the workbook on 6 acceptability criteria on a scale of 1 (very unacceptable) to 5 (very acceptable). The sum of the 6 criteria scores is the total acceptability score. A score of 80% or higher of the maximum score indicates an acceptable intervention. Genetic counselor acceptability scores will be collected through an electronic survey questionnaire. | Immediately after using the workbook with enrolled patients | |
Primary | Practicality | Patient and genetic counselors' perceptions of the workbook practicality will be discussed in qualitative interviews via Zoom. Major themes about practicality will be identified and coded for in the interview transcriptions. Major themes will be compiled. | Immediately after using the workbook with enrolled patients (for genetic counselors) or Post 4 Weeks of Workbook Use (for patients) | |
Primary | Reach of Information About Lynch Syndrome in Family | Reach of Information About Lynch Syndrome in Family will be measured as the number of relatives who were contacted by the patient about Lynch Syndrome in the family. Participants will report the number of relatives contact and discuss the quality of the communication with family members. The outcome will be measured through qualitative interviews via Zoom. Numbers will be recorded and major themes will be coded and compiled. | Post 4 Weeks of Workbook Use | |
Primary | Reach of Genetic Testing Among Family Members | Reach of Genetic Testing Among Family Members will be measured as the number of relatives who sought genetic testing in response to the communication. Patients will report the number of relatives who the patient contacted about Lynch Syndrome in the family who sought genetic testing. Reach of Genetic Testing Among Family Members will be measured through qualitative interviews via Zoom. Numbers will be recorded and major themes will be coded and compiled. | Post 4 Weeks of Workbook Use | |
Secondary | Knowledge of Lynch Syndrome Assessed through Multiple-Choice Questions | Patients will answer 7 multiple choice questions about Lynch Syndrome and its implications for patients and family members. A score of 4 or more questions correct indicates moderate to high knowledge about Lynch Syndrome. The knowledge scores will be measured through an electronic survey. | Post 4 Weeks of Workbook Use | |
Secondary | Perceived Knowledge of Lynch Syndrome Assessed through Confidence Ratings | Patients will rate their confidence in their answer to each of the 7 knowledge questions on a scale of 1 (very low confidence) to 5 (very high confidence). A combined score of 21 or higher suggests moderate to high perceived knowledge. Perceived Knowledge will be measured through an electronic survey. | Post 4 Weeks of Workbook Use | |
Secondary | Patient Self-Efficacy in Communicating about Lynch Syndrome Assessed through Confidence Rating | Patients will score themselves on 5 questions about their confidence in communicating Lynch Syndrome to family members. Scores for each question go from 1 (very low confidence) to 5 (very high confidence). A cumulative score of 15 or higher indicates moderate to high self-efficacy related to family communication. Genetic counselor self-efficacy in communicating about Lynch Syndrome will be measured through an electronic survey. | Post 4 Weeks of Workbook Use | |
Secondary | Genetic Counselor Self-Efficacy in Facilitating Family Testing for Lynch Syndrome Assessed through Confidence Rating | Genetic counselors will score themselves on 5 questions about their confidence in conducting family testing with Lynch Syndrome patients. Scores for each question go from 1 (very low confidence) to 5 (very high confidence). A cumulative score of 15 or higher indicates moderate to high self-efficacy related to facilitating cascade screening in families. Genetic counselor self-efficacy in facilitating family testing for Lynch Syndrome will be measured through an electronic survey. | Immediately after using the workbook with enrolled patients | |
Secondary | Economic Cost of Using Workbook Incurred by Patients | Patients will answer a set of questions about out-of-pocket expenses they incurred while using the workbook along with other resources they needed to complete the workbook. Non-monetary costs will be converted into dollar form. Average cost to the patient will be calculated. We will also estimate average costs across variation in transportation use, number of relatives, employment status and benefits, and incidental costs across participants. Costs will be measured through an electronic survey. | Post 4 Weeks of Workbook Use | |
Secondary | Demand for the Workbook by Other Patients or Health Professionals | Patient and genetic counselor's perceptions of the expected demand for the workbook by other patients with Lynch Syndrome or other health professionals involved in Lynch Syndrome care will be discussed in qualitative interviews conducted via Zoom. Major themes about expected demand will be identified and coded for in the interview transcriptions. Major themes will be compiled. | Immediately after using the workbook with enrolled patients (for genetic counselors) or Post 4 Weeks of Workbook Use (for patients) | |
Secondary | Integration of Workbook into Genetic Counselor Work Environment | Genetic counselors will answer questions about the workbook integration into their workflows and work environment during qualitative interviews conducted via Zoom. Major themes about integration success and challenges will be identified and coded in the interview transcriptions. Major themes will be compiled. | Immediately after using the workbook with enrolled patients |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00217737 -
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
|
Phase 3 | |
Completed |
NCT00905710 -
Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Recruiting |
NCT04909671 -
Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.
|
N/A | |
Recruiting |
NCT04379999 -
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
|
Early Phase 1 | |
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Completed |
NCT01845753 -
Molecular Screening for Lynch Syndrome in Denmark
|
||
Completed |
NCT01216930 -
Molecular Screening for Lynch Syndrome in Southern Denmark
|
N/A | |
Not yet recruiting |
NCT05963191 -
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02912559 -
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
|
Phase 3 | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Withdrawn |
NCT04778566 -
Evaluating the Cologuard Test for Use in Lynch Syndrome
|
||
Completed |
NCT02570516 -
NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome
|
N/A | |
Completed |
NCT01823471 -
I-Scan For Colon Polyp Detection In HNPCC
|
N/A | |
Recruiting |
NCT02813824 -
Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
|
Phase 3 | |
Recruiting |
NCT05078866 -
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT03744962 -
MSI in Circulatory DNA of Endometrial Cancer
|
||
Recruiting |
NCT04711434 -
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
|
Phase 3 | |
Completed |
NCT04131062 -
Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants
|
N/A | |
Recruiting |
NCT05704010 -
Videocapsule Endoscopy in Lynch Syndrome
|
N/A |